About Project
Nine africans partners are involved in this project such are Benin, Cameroon, Democratic Republic of Congo, Ethiopia, Guinea, Mali, Nigeria, Rwanda and Senegal.
In some African partners (Benin and Rwanda) with advanced molecular laboratories, the ‘Deeplex’ assay, a novel multiplex deep sequencing-based drug resistance diagnostic platform that simultaneously provides sequence information of genes that confer resistance to severals key anti-TB drugs has been implemented.
The DIAMA (DIAgnostics for Multidrug resistant tuberculosis in Africa) study aims to address current gaps in the diagnosis and management of patients with Multi-Drug-Resistant (MDR) tuberculosis (TB).
Who We are?
A network of West, Central, East African as well as European instititions
Our Mission
To evaluate and implement rapid and accurate molecular tests for the management of drug resistant tuberculosis to replace the current dependency on culture.
Our Vision
To live in a world where drug resistant tuberculosis is managed without culture
Latest News & Events